Lung Cancer Biomarker Panel for CT Screening Eligibility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lung cancer screening methods, such as those based on the USPSTF criteria, have limited effectiveness in identifying eligible subjects for CT screening, leading to modest life-saving benefits and issues like over-diagnosis and high costs, while existing biomarkers for lung cancer detection lack sufficient sensitivity and specificity.
Innovation Solution
A method and kit for early detection of lung cancer using a panel of biomarkers (CEA, CA125, CYFRA21-1, and Pro-SFTPB) with optional diacetylspermine (DAS) analysis, combined with a regression model to predict lung cancer risk, providing improved discrimination between cases and controls.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If USPSTF criteria are used for lung cancer screening, then screening implementation is simplified, but detection accuracy and identification of eligible subjects is limited
Solution Approach 1:
The patent changes the parameters for screening eligibility from demographic criteria (age, smoking history) to biomarker-based parameters (proteomic profiles, genetic markers). This allows maintaining ease of operation through automated biomarker analysis while significantly improving detection accuracy and identifying eligible subjects who would be missed by traditional criteria.
Solution Approach 2:
The patent replaces the mechanical/demographic screening system with a biochemical system using biomarkers. Instead of relying on questionnaires and demographic data collection, the system uses laboratory-based biomarker detection to identify lung cancer risk, thereby improving precision while maintaining operational simplicity through automated analysis.
2Reliability
If CT screening is performed on all high-risk subjects, then lung cancer detection increases, but over-diagnosis and treatment of benign nodules increases
Solution Approach 1:
The patent implements feedback through biomarker-based risk stratification. By continuously monitoring biomarker levels and comparing them against established thresholds, the system provides feedback on individual cancer risk, allowing CT screening to be targeted only to those with elevated biomarkers, thereby improving detection reliability while reducing over-diagnosis of benign conditions.
Solution Approach 2:
The patent applies local quality by tailoring screening intensity to individual biomarker profiles. Instead of uniform screening, the system identifies subjects with specific biomarker patterns that indicate high cancer risk, concentrating CT screening resources on those local cases most likely to benefit, thereby reducing overall over-diagnosis while maintaining high detection reliability for true positives.
3Measurement precision
If multiple biomarkers are analyzed, then detection accuracy improves, but test complexity and cost increases
Solution Approach 1:
The patent segments the complex biomarker analysis into modular components. Instead of analyzing all possible biomarkers simultaneously, the system divides the panel into specific marker groups (proteomic markers, genetic markers, metabolites) that can be analyzed separately and combined, reducing computational complexity and cost while maintaining high detection accuracy through integrated evaluation.
Solution Approach 2:
The patent creates a universal biomarker panel that serves multiple functions: risk stratification, diagnostic confirmation, and monitoring. This multi-functional approach improves detection accuracy across different clinical scenarios while avoiding the need for separate specialized tests, thereby managing complexity through a single comprehensive panel rather than multiple discrete assays.
Data Source
AI summary
Provided are methods and related kits for detection of early stage lung cancer, and determination of risk of harboring lung cancer.